GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Reshape Lifesciences Inc (STU:24O0) » Definitions » Debt-to-Asset

Reshape Lifesciences (STU:24O0) Debt-to-Asset : 0.03 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Reshape Lifesciences Debt-to-Asset?

Reshape Lifesciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.10 Mil. Reshape Lifesciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.12 Mil. Reshape Lifesciences's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was €7.57 Mil. Reshape Lifesciences's debt to asset for the quarter that ended in Mar. 2024 was 0.03.


Reshape Lifesciences Debt-to-Asset Historical Data

The historical data trend for Reshape Lifesciences's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reshape Lifesciences Debt-to-Asset Chart

Reshape Lifesciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.36 0.01 0.02 0.03

Reshape Lifesciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.03 0.04 0.03 0.03

Competitive Comparison of Reshape Lifesciences's Debt-to-Asset

For the Medical Devices subindustry, Reshape Lifesciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Reshape Lifesciences's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Reshape Lifesciences's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Reshape Lifesciences's Debt-to-Asset falls into.



Reshape Lifesciences Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Reshape Lifesciences's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Reshape Lifesciences's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Reshape Lifesciences  (STU:24O0) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Reshape Lifesciences Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Reshape Lifesciences's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Reshape Lifesciences (STU:24O0) Business Description

Traded in Other Exchanges
Address
1001 Calle Amanecer, San Clemente, CA, USA, 92673
Reshape Lifesciences Inc is a developer of minimally invasive medical devices to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.

Reshape Lifesciences (STU:24O0) Headlines

No Headlines